FDA's ANDA Steering Cmte.
Met with the Generic Pharmaceutical Industry Assn. and Natl. Pharmaceutical Alliance Oct. 16 for recommendations on implementation of the ANDA/Patent Restoration bill. Cmte. is also scheduled to meet with PMA Nov. 6 and NAPM Nov. 8. Headed by Deputy Com. Novitch, the cmte. also includes Generic Drug Div. Director Marvin Seife, Office of Drug Standards Director Peter Rheinstein, Associate Com. for Legislation and Information Robert Wetherell, Associate Com. for Management and Operations Gerald Meyer and Office of Drug Standards Deputy Director James Morrison
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.